1794 – Irreversible Electroporation (IRE) for prostate tumour tissue in patients with prostate cancer

New Medicare Benefits Schedule item.

Irreversible Electroporation (IRE) is an ablation procedure that uses the NanoKnife system to destroy soft tissue tumours. The system applies electrical pulses using electrodes placed around the tumour. This creates holes in the cell membranes, resulting cell death. IRE is non-thermal technology and can be used to treat tumours that are near critical structures such as nerves, blood vessels and the urethra.
 

Type: Therapeutic

Prostate cancer is a tumour that arises in the prostate gland. As with any cancer, if it is advanced or left untreated in early stages, it can eventually spread throughout the blood. It is estimated that by age 85, one in six males will be diagnosed with prostate cancer. 
 

The following consultation deadlines apply:

• Pre-PASC consultation deadline: 14 March 2025
• Pre-MSAC consultation deadline: -

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 16 to 17 April 2025
• ESC meeting: -
• MSAC meeting: -

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.